Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > New post on LinkedIn

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Nov 18, 2021 5:25pm

143 Views

Post# 34143011

RE:New post on LinkedIn

Well, at the risk of embarassing yourself infront of whole Province, I guess this means we can assume they are seeing good things in the trial!

scarlet1967 wrote:
“Theratechnologies will be in the spotlight this Thursday, November 18 at 6:30 pm on the television channel TVA nouvelles in the program " vos affaires" of Pierre-Olivier Zappa. The work done by the researchers on the #oncologie platform will be honored, including interviews with Dr. Bliveau and Paul Levesque.”

https://www.linkedin.com/posts/theratechnologies-inc_%C3%A9mission-de-t%C3%A9l%C3%A9-%C3%A0-vos-affaires-activity-6867174824389808128-vSR-